Yahoo! Finance Canada report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
Why HTFL Stock dropped -2.44% Today — RQD Quant Desk Flash
Heartflow Inc. (HTFL) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HTFL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Heartflow Inc. (NASDAQ: HTFL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $59.05 (-2.44% 1D, market cap $5.26B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HTFL ranks #256 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HTFL compare to MMED and HAE in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), HTFL carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 76.8%, and ROIC of -12.0%. By comparison, MMED (MiniMed Group Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -3.9%, cap $5.42B) and HAE (Haemonetics Corporation) posts a B grade (74/100 RQD, P/E N/A, ROIC 8.4%, cap $5.45B). Among the 5-stock peer group, MMSI leads on earnings multiple (43.4x) while HAE leads on capital efficiency (8.4% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HTFL?
▼
Per HTFL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001464521), Heartflow Inc. generated $176.0M in revenue (+39.9% YoY), -$116.8M in net income, and -$59.0M in free cash flow against $359.5M in total assets and $26.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±11.5% realized swing band)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a HTFL Turnaround Squeeze
While HTFL currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($51.24) and Max Pain ($62.00) forces dealer call-delta covering toward $68.11.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why HTFL Stock dropped -2.44% Today — RQD Quant Desk Flash
Heartflow Inc. (HTFL) dropped -2.44% to $59.05, trading at 96% of its 52-week range ($20.13 – $60.56). Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 96% of its 52-week range ($20.13 – $60.56) with RSI-14 at 69.9 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.5% around $59.05 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 76.8% gross margin and $0 annual free cash flow.
Yahoo Finance Singapore report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
First plaque tool with prospective outcomes data. Faster, sustained LDL-C control: approximately 50% of patients reached goal by 90 days vs. approximately 35% with CCTA alone. GAMEFILM data highlight high prevalence of
Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions NAVI
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HTFL)
- ✓Walkthrough of HTFL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
HTFL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +39.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HTFL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HTFL. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HTFL)
1. Head-to-Head Health Care Peer Comparison (HTFL vs. MMED, HAE, STVN, MMSI)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Heartflow Inc. (HTFL) ranks #256 by composite RQD confidence (53/100, grade D+) and #161 by equity capitalization ($5.26B). Within this direct 5-issuer industry benchmark cohort, MMSI leads on earnings valuation at 43.4x trailing P/E, while HAE leads on capital efficiency and profitability with 8.4% ROIC and 59.0% gross margin. MMSI currently holds the highest overall quantitative score in the immediate peer group at 75/100 (B) compared with HTFL at 53/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HTFL
ACTIVE
Heartflow Inc. | D+ | 53/100 | — | 76.8% | -12.0% | -2.44% | $5.26B | Benchmark Subject |
| MMED MiniMed Group Inc. | D | 46/100 | — | 54.2% | -3.9% | -5.04% | $5.42B | /mmed-vs-htfl → |
| HAE Haemonetics Corporation | B | 74/100 | — | 59.0% | 8.4% | -0.12% | $5.45B | /hae-vs-htfl → |
| STVN Stevanato Group S.p.A. | D+ | 58/100 | — | — | — | -4.25% | $5.53B | /stvn-vs-htfl → |
| MMSI Merit Medical Systems Inc. | B | 75/100 | 43.4x | 48.7% | 7.8% | -7.66% | $5.58B | /mmsi-vs-htfl → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001464521In its most recent audited fiscal period (FY2025, filed 2025-12-31), Heartflow Inc. (HTFL) reported GAAP revenue of $176.0M (+39.9% vs. FY2024 revenue of $125.8M , and +101.9% cumulative change since FY2023) , GAAP net income of -$116.8M, operating cash flow of -$54.0M, and free cash flow of -$59.0M (+19.5% YoY). On the balance sheet, HTFL closed FY2025 with $359.5M in total assets against $26.5M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $176.0M | -$116.8M | -$54.0M | -$59.0M | $359.5M | $26.5M |
| FY2024 (FY) | 2024-12-31 | $125.8M | -$96.4M | -$69.0M | -$73.4M | $118.7M | $94.3M |
| FY2023 (FY) | 2023-12-31 | $87.2M | -$95.7M | -$76.4M | -$80.4M | $2.89B | $677.4M |
3. HTFL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HTFL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Heartflow Inc. (NASDAQ: HTFL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $59.05 (-2.44% 1D, market cap $5.26B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HTFL ranks #256 in composite RQD confidence.
How does HTFL compare to MMED and HAE in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), HTFL carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 76.8%, and ROIC of -12.0%. By comparison, MMED (MiniMed Group Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -3.9%, cap $5.42B) and HAE (Haemonetics Corporation) posts a B grade (74/100 RQD, P/E N/A, ROIC 8.4%, cap $5.45B). Among the 5-stock peer group, MMSI leads on earnings multiple (43.4x) while HAE leads on capital efficiency (8.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HTFL?
Per HTFL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001464521), Heartflow Inc. generated $176.0M in revenue (+39.9% YoY), -$116.8M in net income, and -$59.0M in free cash flow against $359.5M in total assets and $26.5M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HTFL trading relative to its 50-day, 200-day, and 52-week technical levels?
HTFL last traded at $59.05 (-2.44% on volume of 2,247,387 shares), positioning the stock +15.24% above its 50-day simple moving average ($51.24) and +71.91% above its 200-day simple moving average ($34.35). Across its 52-week range of $20.13 to $60.56, HTFL sits at the 96.3% percentile with a 14-day RSI of 69.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.5% ($52.26 to $65.84).
HTFL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is HTFL stock moving today?
Why HTFL Stock dropped -2.44% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.
HTFL — Heartflow Inc.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, HTFL scores 53 out of 100, a letter grade of D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine at 10 / 20 (ROIC of -12% and FCF yield of -1.12%); Whale 13F Flow at 18 / 20 (institutional accumulation and options positioning); Insider Conviction at 5 / 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 9 / 20 (Beta of 0.9 and sector sensitivity); and Forensic Balance Sheet at 11 / 20 (Altman Z-Score of 26, Piotroski F-Score of 5/9, Debt/Equity of 0.08).
For a prospective investor, the weakest pillars are the cash engine and insider conviction, while institutional flow is the strongest. The cash-generation pillar reflects negative ROIC and a negative FCF yield, meaning the business is not currently returning capital on its invested base per the source data. The balance-sheet pillar is comparatively supportive, with low leverage and a high Altman Z-Score, which suggests near-term solvency is not the principal concern in the source data. The insider pillar is low, indicating limited insider buying conviction in the cited flows. The upside case rests mainly on institutional positioning and any future improvement in cash generation; the valuation tradeoff is that the stock trades at a Forward P/E of 27 while reported EPS (TTM) is -1.34. The rating implies that the current price is not supported by present cash economics according to the RQD framework. This is an analytical read of the source data, not personalized financial advice.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $176.0M | $-64.1M | $-116.8M | N/A | $-59.0M | $44.8M | $26.5M |
| FY 2024 | $125.8M | $-61.2M | $-96.4M | N/A | $-73.4M | $51.4M | $94.3M |
| FY 2023 | $87.2M | $-72.9M | $-95.7M | N/A | $-80.4M | N/A | $677.4M |
Per the SEC financials, revenue rose from $87.2M in FY 2023 to $176.0M in FY 2025 while operating and net losses persisted in each period. Per the market data, operating margin is -36.4% and net margin is -60%, against a gross margin of 76.8%. ROIC is -12%. Per the Roarable RQD rating, the Altman Z-Score is 26, the Piotroski F-Score is 5/9, and Debt/Equity is 0.08; reported debt declined from $677.4M in FY 2023 to $26.5M in FY 2025.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts section, the headlines include: a Piper Sandler price-target raise citing a "competitive moat" (rated GREEN, CATALYST); a GuruFocus report on "Pivotal CT-Guided PCI Data at TCT Meeting" (YELLOW); and a Stock Titan item noting an officer proposal to sell 5,654 shares around October 22, 2026 (YELLOW). Other items from Yahoo! Finance Canada, Yahoo Finance Singapore, and TradingView are generic market-wire summaries (YELLOW) without specific catalyst content. Risk watch items include the insider share-sale proposal. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are present.
Open Questions
- What is the company's specific product portfolio and revenue mix behind the 76.8% gross margin?
- What is the source of the reported P/E (TTM) and EV/EBITDA gaps, and when will positive earnings be expected?
- What is the EPS reported for FY 2023 through FY 2025, since the financials table lists EPS as N/A?
- What is the cash balance for FY 2023, which is listed as N/A?
- What do the named institutional and insider holders hold, given that the holders section is empty?
HTFL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Heartflow Inc. (HTFL) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance Singapore report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Heartflow Inc. (HTFL) market action, institutional positioning, and fundamental catalysts.
HTFL Bull vs. Bear Conversation Board — What's Your Call at $59.05?
🔥 Official Bull vs. Bear Debate: Is HTFL (D+ • RQD 53/100) a Buy at $60.53?
Welcome to the HTFL (Heartflow Inc.) Roar Pit. Current RQD Composite is 53/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on HTFL — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on HTFL, but look at what you are paying: current EV/EBITDA multiples with 76.8% gross margins. Unless Heartflow Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
HTFL cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on HTFL, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $60.53 (52-wk range $20.13 - $60.56), any beat on forward guidance forces shorts and underweight funds to chase.